Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. - Wikidata - wikimedia - TriplyDB

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q33404348

about

Trial Watch: Proteasomal inhibitors for anticancer therapy Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma.Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.Perspectives in the treatment of multiple myeloma.An old drug with a new future: bendamustine in multiple myeloma.Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes.Future agents and treatment directions in multiple myeloma.Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma.Salvage therapy of multiple myeloma: the new generation drugs.Bendamustine in multiple myeloma.Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors.Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma.Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).Venous thromboembolism in patients with myeloma: incidence and risk factors in a "real-world" population.United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma.Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.

P2860

Q28082910-308C31E6-9A72-4229-8543-51BEF87B92CD Q30828090-A85A3D41-A94F-4EE7-B589-E3D08328BD73 Q33410756-89CBC6BC-2F7A-4BB5-B092-3CE6AD0C2DF7 Q33411440-068B1085-4EED-4E2F-B2A6-80A3AB943359 Q33411708-C348DE2B-9404-4679-AD44-DC6335BC8B9F Q33418389-AAF139F7-1547-4506-AFDD-64947F7A09C8 Q33437691-51DB4DF3-4DCE-49A5-B7A6-EFD9733CB949 Q33442039-BE4BB9AE-D7DE-464D-8D97-6551F9A1844C Q37469859-F928D9DB-0B81-4B89-8608-AC4F6EAC9AC9 Q38095526-4544A3E6-9D83-4DFC-856C-EB2F8FD49EFA Q38108391-687FBFC1-7775-4967-9886-6376FA5995EF Q38139989-72AD8F28-D05B-4D1F-B7FB-29CBF1C5503C Q38152510-E1022C8A-9BDF-4A9E-BC33-8E03F03FBE7B Q38172300-FFEF6D17-A55D-4837-9668-A3A921A7C4B4 Q38206120-603EC36D-C2DA-446A-8BAA-F8CEC790E5F8 Q38223433-D1581FFE-18D5-4551-9842-669C83197D93 Q38530583-DEAC28F0-C67A-4A46-9925-682D103BA2E1 Q38548134-7555F40A-0966-424D-A3F4-3EEE06838996 Q38642648-C74893A4-0215-4CE8-A161-4BA85C082CAD Q38672091-7F3A85B9-FC2B-411F-96F3-C767BE064DBC Q39048347-79C642EF-80B5-4B94-B49D-39D3D00203F1 Q39177792-3BD3156B-02D0-415F-AD18-27B7E513DC4E Q40095723-FE372165-7AD6-4AAB-88B0-B1337DC792B3 Q41044036-D1A74418-01D2-4072-AC62-3D0AEB31DC70 Q41253617-4CA74F5B-7ABB-4CCD-8F0B-D2DA8F49431A Q41602187-7CD86C26-A426-4C34-9503-21C0F39CF66E Q44006947-0BC7804A-1DB5-4D87-9AA1-3FE61A9B05ED Q45892519-16402914-0DDD-471A-AA72-86079F0A8417 Q48204298-2B8BD06C-B4AB-499F-A3DB-3FF93B76CA31 Q50726885-D9E73051-D6FF-41DC-B87E-9402DF7A7E73 Q52841629-7F9CC549-E79B-463A-84EE-83EA7158D667 Q52958098-8D8D6695-5E04-4966-9546-7C9EE5E180C9 Q53504691-7FEC5E3C-63E0-45DC-AE6E-BA7F100C919F

P2860

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q33404348

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Phase I/II trial assessing ben ...... r refractory multiple myeloma.

@ast

Phase I/II trial assessing ben ...... r refractory multiple myeloma.

@en

type

label

Phase I/II trial assessing ben ...... r refractory multiple myeloma.

@ast

Phase I/II trial assessing ben ...... r refractory multiple myeloma.

@en

prefLabel

Phase I/II trial assessing ben ...... r refractory multiple myeloma.

@ast

Phase I/II trial assessing ben ...... r refractory multiple myeloma.

@en

P1433

Q33404348-018874B9-634E-4651-AF40-492DB7D4D548

P1476

Q33404348-A4F0B271-830D-461D-B312-F710D2AD5F2D

P2093

Q33404348-2F01F269-696F-43DA-9285-FE65214A8F49

Q33404348-62FC37C6-C550-4E32-B3C6-BB89CAAFDB42

Q33404348-6900A94F-BE8E-4D17-BAC5-31660857BD7A

Q33404348-7CD5BB66-43CA-4E98-8CC4-D774DB37654F

Q33404348-8304C242-5E82-47C6-B28E-3E09826D72F6

Q33404348-9E4219FD-C3FF-42ED-9863-C3D6BFE6EDDF

Q33404348-A1FDCC65-A2F1-4E3B-BC55-7E165021661B

Q33404348-AC01306F-FD05-4C3F-ACDD-261015B9B703

Q33404348-C5B32C46-DCDE-40E6-8A57-6B761DB76EB2

Q33404348-DE7713C9-FB53-4A0C-9027-EB2E29619059

P2860

Q33404348-0AF11281-EC77-4A1C-A3E1-67A95C732DFA

Q33404348-0B7D5704-E57D-4106-8527-7B2FDD7CB704

Q33404348-10F98169-7DBA-40E8-99AE-C67C7C50014D

Q33404348-179ADEA1-1940-4FCF-83C7-C9F5A8A1729F

Q33404348-235E73D7-150B-4C93-B0B9-C1A850798232

Q33404348-24A7B741-5C8D-4A39-B462-6ABCE65E7D3E

Q33404348-2EC49C29-660A-4E25-BC28-62D88AA4B45C

Q33404348-3AA74B8B-AE17-4AD1-87BB-E859EC505152

Q33404348-3C09EBBE-95DE-45F2-A969-FFAA16B08F24

Q33404348-3D22E20C-33B8-420D-B11C-6753482F3199

P304

Q33404348-6553C3C5-110E-4E77-9F29-915240EA6CEC

P31

Q33404348-4E813074-017E-45CD-9595-AE470CFEF56D

P356

Q33404348-0093A8D3-47CE-4C67-9873-719874036A57

P407

Q33404348-2EFB294F-5B3D-4293-BC1A-C094F7382D42

P433

Q33404348-EC48FB92-69C3-4713-BC1C-B0193B99C17B

P478

Q33404348-B1D021AD-2CAC-4680-ABDD-4653682908D4

P577

Q33404348-8F7C78E6-E7C5-4ACD-ACD7-30B12FDE7932

P5875

Q33404348-D6AC2BA7-AEB6-41CF-94CD-B52427556536

P698

Q33404348-A632C851-85AB-4C61-A25E-5EE72322882A

P921

Q33404348-26617749-2588-41FD-8CB7-029A5D673D40

Q33404348-51CD7224-C463-4B1A-BAAE-BE68A6DD57D0

P356

P1433

British Journal of Haematology

P1476

Phase I/II trial assessing ben ...... r refractory multiple myeloma.

@en

P2093

Alberto Bessudo

http://www.w3.org/2001/XMLSchema#string

Debra Mayo

http://www.w3.org/2001/XMLSchema#string

Dipti Patel-Donnelly

http://www.w3.org/2001/XMLSchema#string

Donald S Gravenor

http://www.w3.org/2001/XMLSchema#string

Edward J Gorak

http://www.w3.org/2001/XMLSchema#string

James R Berenson

http://www.w3.org/2001/XMLSchema#string

Ori Yellin

http://www.w3.org/2001/XMLSchema#string

Ralph V Boccia

http://www.w3.org/2001/XMLSchema#string

Regina A Swift

http://www.w3.org/2001/XMLSchema#string

Robert S Siegel

http://www.w3.org/2001/XMLSchema#string

P2860

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

A phase 2 study of bortezomib in relapsed, refractory myeloma.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.

Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.

Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma.

A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.

P304

321-330

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.12129

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

160

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233417605

http://www.w3.org/2001/XMLSchema#string

P698

23150919

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

phase II clinical trial